TICKERNERD
Menu
NRXPNRXPHealthcare · Biotechnology

NRXP Stock Forecast: NRX Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 7 Aug 2026
$3.58
+15.70% on the day

The 4 Wall Street analysts covering NRX Pharmaceuticals, Inc. hold a median 12-month price target of $47 — +1214.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 20 of 100 as at 8 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$153.2M
Ticker Nerd rank
20 / 100
Median analyst target
$47
Analysts covering
4
Total return, dividends reinvested
1W
+13.5%
1M
−14.1%
YTD
+31.9%
1Y
+45.3%
From 52W high
−22.6%
From 52W low
+112.8%
$1.68
$4.62
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NRXP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores NRX Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Aug 2026
20 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
72
Momentum
64
Issuance
63
Accruals
45
Growth
39
Revisions
26
Volatility
15
Value
11
Quality
6

Size (72): Smaller than most of the companies we track.

Quality (6): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

The rank is the raw material. Whether the rules would actually own NRX Pharmaceuticals, Inc. — and when they’d sell — is the membership.

Wall Street

NRXP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NRXP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$10.00$20.00$30.00$40.00$50.00Oct 25Jan 26Apr 26Jul 26NRXPHigh $49Median $47Low $25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $25Median $47High $49

The green dot is the last close — the median target sits +1214.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
5 May 2026D. Boral CapitalMaintainsBuy$34
27 Apr 2026Ascendiant CapitalMaintainsBuy—
27 Apr 2026HC Wainwright & Co.ReiteratesBuy—
23 Apr 2026D. Boral CapitalMaintainsBuy—
20 Apr 2026D. Boral CapitalMaintainsBuy—
24 Mar 2026BTIGReiteratesBuy—
24 Mar 2026D. Boral CapitalMaintainsBuy—
17 Mar 2026D. Boral CapitalMaintainsBuy—
16 Mar 2026D. Boral CapitalMaintainsBuy—
9 Mar 2026D. Boral CapitalMaintainsBuy—
3 Mar 2026HC Wainwright & Co.MaintainsBuy—
18 Feb 2026BTIGReiteratesBuy—
17 Feb 2026D. Boral CapitalMaintainsBuy—
15 Jan 2026BTIGReiteratesBuy—
5 Jan 2026D. Boral CapitalMaintainsBuy—
2 Jan 2026Ascendiant CapitalMaintainsBuy—
16 Dec 2025HC Wainwright & Co.ReiteratesBuy—
3 Dec 2025BTIGReiteratesBuy—
3 Dec 2025D. Boral CapitalMaintainsBuy—
2 Dec 2025D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

NRXP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−376.9%
Analysts raising
0
Analysts cutting
1
Fundamentals

NRX Pharmaceuticals, Inc. (NRXP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.4×

Cheaper than 72% of US stocks

Price / sales
66.8×

Cheaper than 5% of US stocks

Price / book
−8.4×

Cheaper than 97% of US stocks

EV / EBITDA
−7.3×

Cheaper than 81% of US stocks

Growth & margins
Revenue growth (YoY)
8.6%

Higher than 49% of US stocks

Earnings growth (YoY)
—
Gross margin
40.9%

Higher than 52% of US stocks

Operating margin
−444.6%

Higher than 8% of US stocks

Net margin
58.8%

Higher than 97% of US stocks

Returns & dividend
Return on equity
179.6%

Higher than 98% of US stocks

Return on assets
−110.2%

Higher than 2% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

NRXP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NRXPNRX Pharmaceuticals, Inc.$153.2M
20
MENSJyong Biotech Ltd.$150.7M
4
MISTMilestone Pharmaceuticals, Inc.$151.9M
14
CNTNCanton Strategic Holdings, Inc.$144.2M
13
TNYATenaya Therapeutics, Inc.$157.4M
38
CDXSCodexis, Inc.$158.1M
58
ENTXEntera Bio Ltd.$141.3M
45
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NRXP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest NRXP news & analysis

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans

GlobeNewsWire · 7 Aug 2026positive

NRx Pharmaceuticals announced it will host a conference call and Q&A session on Monday, August 10, 2026 at 8:30 a.m. Eastern Time to discuss the FDA's completion of the first-cycle review of the Company's ANDA for preservative-free ketamine, which was announced earlier that day.

Why it matters — The call addresses the FDA's first-cycle review completion for the Company's preservative-free ketamine ANDA and its commercial plans, which is relevant to NRXP watchers tracking the product's regulatory progress.

FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval

GlobeNewsWire · 7 Aug 2026positive

The FDA completed its first-cycle review of NRX Pharmaceuticals' preservative-free ketamine ANDA, finding no major deficiencies related to the drug product, ingredients, labeling, or CMC. The only remaining item is manufacturer certification for a luer lock vial, which is already used in three FDA-approved ANDA products.

Why it matters — This indicates the ketamine ANDA is close to final approval, with only a packaging certification step remaining after a clean first-cycle review.

FAQ

Frequently asked questions about NRXP stock

What is the NRXP stock price forecast for 2026-2027?

The 4 Wall Street analysts covering NRX Pharmaceuticals, Inc. have a median 12-month price target of $47, with estimates ranging from $25 to $49. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NRXP stock a buy right now?

Of the 4 analysts covering NRX Pharmaceuticals, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NRX Pharmaceuticals, Inc. 20 out of 100 across roughly 4,600 US stocks as at 8 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NRXP?

As at 8 Aug 2026, NRX Pharmaceuticals, Inc. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (72 of 100).

Will NRXP stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +1214.7% from the last close, and Ticker Nerd's factor model ranks NRX Pharmaceuticals, Inc. 20 out of 100 as at 8 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NRXP stock forecast for 2030?

No analyst covering NRX Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NRXP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $49 over the next 12 months.

How has NRXP stock performed over the past year?

NRX Pharmaceuticals, Inc. returned +45.3% over the 12 months to 7 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does NRX Pharmaceuticals, Inc. do?

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for central nervous system disorders with high unmet medical need.

What is the latest news on NRXP?

The most recent item we track (GlobeNewsWire, 7 Aug 2026): "NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans". NRx Pharmaceuticals announced it will host a conference call and Q&A session on Monday, August 10, 2026 at 8:30 a.m. Eastern Time to discuss the FDA's completion of the first-cycle review of the Company's ANDA for preservative-free ketamine, which was announced earlier that day.

Company

About NRX Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for central nervous system disorders with high unmet medical need. The company concentrates on severe psychiatric and neurological conditions, particularly suicidal depression, suicidal bipolar depression, chronic pain, and post-traumatic stress disorder. Its pipeline is built around an NMDA-targeted platform, including NRX-100, a preservative-free intravenous ketamine formulation, and NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone being studied in Phase 2/3 settings. These products aim to address acute suicidality and related symptoms where existing therapies are limited or inadequate, and have received U.S. FDA designations such as Fast Track and Breakthrough Therapy for specific indications. NRx Pharmaceuticals also operates through related segments and initiatives in interventional psychiatry and healthcare delivery. Founded in 2017 and headquartered in Wilmington, Delaware, the company plays a specialized role in the biopharmaceutical market by targeting life-threatening mental health conditions and complex CNS disorders with differentiated, mechanism-based drug candidates.

CEO Dr. Jonathan C. Javitt M.D., M.P.H. · 29 employees · United States · https://www.nrxpharma.com